Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.’s Q3 2017 Earnings (TTPH)

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Research analysts at SunTrust Banks reduced their Q3 2017 earnings per share (EPS) estimates for Tetraphase Pharmaceuticals in a report released on Thursday. SunTrust Banks analyst E. Nash now forecasts that the biopharmaceutical company will post earnings per share of ($0.76) for the quarter, down from their prior estimate of ($0.61). SunTrust Banks also issued estimates for Tetraphase Pharmaceuticals’ Q4 2017 earnings at ($0.61) EPS, FY2017 earnings at ($2.97) EPS and FY2018 earnings at ($1.69) EPS.

TTPH has been the topic of several other reports. Piper Jaffray Companies started coverage on Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They set an “overweight” rating and a $14.00 price objective on the stock. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research report on Saturday, September 23rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $12.96.

ILLEGAL ACTIVITY NOTICE: “Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.’s Q3 2017 Earnings (TTPH)” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://transcriptdaily.com/2017/10/09/equities-analysts-set-expectations-for-tetraphase-pharmaceuticals-inc-s-q3-2017-earnings-ttph.html.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 7.76 on Monday. The company’s 50-day moving average price is $6.79 and its 200-day moving average price is $7.29. Tetraphase Pharmaceuticals has a 1-year low of $3.11 and a 1-year high of $9.93. The firm’s market capitalization is $396.17 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The firm had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. During the same period last year, the company posted ($0.47) earnings per share. The firm’s quarterly revenue was up 28.2% compared to the same quarter last year.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the sale, the insider now directly owns 17,500 shares of the company’s stock, valued at approximately $105,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. lifted its holdings in shares of Tetraphase Pharmaceuticals by 6.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 7,866 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tetraphase Pharmaceuticals by 16.4% during the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after purchasing an additional 230,420 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Tetraphase Pharmaceuticals by 3.4% during the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 6,114 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Tetraphase Pharmaceuticals by 17.0% during the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 45,554 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Tetraphase Pharmaceuticals by 180.4% during the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 408,078 shares during the last quarter. Hedge funds and other institutional investors own 41.73% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply